Deutsche Bank Turns Bearish on Novartis as Shares Rebound

Deutsche Bank has adopted a bearish view on Novartis, shifting its stance as the pharmaceutical group’s shares recover from the losses triggered by a failed clinical trial. The move puts the broker at odds with the stock’s recent rebound and signals a more cautious assessment of the company’s outlook.

The shares had come under pressure after the trial setback, which raised questions about near-term prospects and weighed on investor sentiment. Since then, the stock has clawed back ground, suggesting that some market participants see the reaction as overdone or are looking beyond the disappointment.

Deutsche Bank’s more negative position therefore stands out against that recovery. With no detailed rationale provided in the headline item, the shift appears to reflect a broader reappraisal of risk rather than a specific new event. Investors will likely watch whether other analysts follow or push back.

For now, the contrast between the recovering share price and the bearish broker call leaves Novartis in focus. The stock’s ability to hold its rebound may depend on how convincingly the company can address concerns raised by the trial failure and restore confidence in its pipeline.